GlassScriptPhysician profile
Ingrid E Flores-Freeth
NPI 1609832211
$727.10
in general payments reported to CMS, 2019-2025
12 companies · $519 in 2025
The $519 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.91 · 2020: $23.67 · 2021: $59.94 · 2022: $80.77 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $330.83 |
| Education | $187.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $277.14 | 2025 | Veozah |
| Exeltis, USA INC. | $101.55 | 2025 | Slynd |
| Hologic Sales and Service, LLC | $81.25 | 2021-2025 | Aptima |
| Abbvie INC. | $52.03 | 2019-2022 | |
| Myovant Sciences INC. | $50.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.50 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.38 | 2025 | Vpriv |
| Shield Therapeutics INC | $24.31 | 2025 | |
| Lupin INC. | $23.67 | 2020 | |
| Amag Pharmaceuticals, INC. | $21.83 | 2019 | |
| Millicent US INC | $19.01 | 2025 | Femlyv |
| Biogen, INC. | $18.61 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingrid Flores-Freeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.